초록 ▼

A non-invasive measurement of biological tissue reveals information about the function of that tissue. Polarized light is directed onto the tissue, stimulating the emission of fluorescence, due to one or more endogenous fluorophors in the tissue. Fluorescence anisotropy is then calculated. Such meas

A non-invasive measurement of biological tissue reveals information about the function of that tissue. Polarized light is directed onto the tissue, stimulating the emission of fluorescence, due to one or more endogenous fluorophors in the tissue. Fluorescence anisotropy is then calculated. Such measurements of fluorescence anisotropy are then used to assess the functional status of the tissue, and to identify the existence and severity of disease states. Such assessment can be made by comparing a fluorescence anisotropy profile with a known profile of a control.

대표청구항 ▼

1. An apparatus for non-invasively evaluating human tissue comprising: a stimulator configured to stimulate a resting tissue to change its metabolism and become a stimulated tissue;a light source configured to irradiate the resting and stimulated tissue with polarized light so as to cause an endogen

1. An apparatus for non-invasively evaluating human tissue comprising: a stimulator configured to stimulate a resting tissue to change its metabolism and become a stimulated tissue;a light source configured to irradiate the resting and stimulated tissue with polarized light so as to cause an endogenous fluorophor in the tissue to fluoresce;a determination module configured to determine a resting steady-state fluorescence anisotropy of emitted fluorescence in the resting tissue and a stimulated steady-state fluorescence anisotropy of emitted fluorescence in the stimulated tissue; anda computing module configured to: construct a resting fluorescence anisotropy map based on the resting steady-state fluorescence anisotropy and a stimulated fluorescence anisotropy map based on the stimulated steady-state fluorescence anisotropy;determine a functional capacity of the tissue by subtracting the resting fluorescence anisotropy map from the stimulated fluorescence anisotropy map; andcompare the functional capacity of the tissue to a functional capacity of a control tissue similarly evaluated to identify a tissue dysfunction. 2. The apparatus of claim 1, wherein the stimulator is configured to administer supplemental oxygen. 3. The apparatus of claim 1, wherein the stimulator is configured to administer glucose. 4. The apparatus of claim 1, wherein: the determination module is further configured to measure steady-state fluorescence anisotropy values for a plurality of locations at a plurality of depths in the resting and stimulated tissue; andthe computing module is further configured to: construct a resting three-dimensional map of steady-state fluorescence anisotropy based on the steady-state fluorescence anisotropy values for the resting tissue and a stimulated three-dimensional map of steady-state fluorescence anisotropy based on the steady-state fluorescence anisotropy values for the stimulated tissue; anddetermine the functional capacity of the tissue by subtracting the resting three-dimensional map from the stimulated three-dimensional map. 5. The apparatus of claim 1, wherein the computing module is configured to determine the functional capacity of the tissue by subtracting point by point or pixel by pixel the resting fluorescence anisotropy map from the stimulated fluorescence anisotropy map over the entire maps or within an area of interest. 6. The apparatus of claim 1, wherein the tissue dysfunction comprises presence and severity of a disease. 7. The apparatus of claim 6, wherein the disease comprises cancer. 8. The apparatus of claim 6, wherein the disease is selected from the group consisting of ocular posterior pathologies including diabetic retinopathy, age-related macular degeneration and primary open angle glaucoma, and other optic neuropathies. 9. The apparatus of claim 1, wherein the stimulator comprises a light source configured to irradiate the tissue with steady-state light and the tissue is selected from the group consisting of skin tissue, cervix tissue, abdominal tissue, esophagus tissue, stomach tissue, gut tissue, lung tissue, and ocular tissue. 10. The apparatus of claim 9, wherein a wavelength of the steady-state light is selected from a range between 400 and 700 nm. 11. The apparatus of claim 1, wherein the computing module is further configured to determine, based at least in part on the functional capacity of the tissue, an efficacy of a treatment intervention. 12. A method for non-invasively evaluating human tissue comprising: stimulating a resting tissue to change its metabolism and become a stimulated tissue;irradiating the resting and stimulated tissue with polarized light so as to cause an endogenous fluorophor in the tissue to fluoresce;determining a resting steady-state fluorescence anisotropy of emitted fluorescence in the resting tissue and a stimulated steady-state fluorescence anisotropy of emitted fluorescence in the stimulated tissue;constructing a resting fluorescence anisotropy map based on the resting steady-state fluorescence anisotropy and a stimulated fluorescence anisotropy map based on the stimulated steady-state fluorescence anisotropy;determining a functional capacity of the tissue by subtracting the resting fluorescence anisotropy map from the stimulated fluorescence anisotropy map; andcomparing the functional capacity of the tissue to a functional capacity of a control tissue similarly evaluated to identify a tissue dysfunction. 13. The method of claim 12, wherein the stimulating comprises administering supplemental oxygen. 14. The method of claim 12, wherein the stimulating comprises administering glucose. 15. The method of claim 12, further comprising: measuring steady-state fluorescence anisotropy values for a plurality of locations at a plurality of depths in the resting and stimulated tissue;constructing a resting three-dimensional map of steady-state fluorescence anisotropy based on the steady-state fluorescence anisotropy values for the resting tissue and a stimulated three-dimensional map of steady-state fluorescence anisotropy based on the steady-state fluorescence anisotropy values for the stimulated tissue; anddetermining the functional capacity of the tissue by subtracting the resting three-dimensional map from the stimulated three-dimensional map. 16. The method of claim 12, wherein determining the functional capacity of the tissue comprises subtracting point by point or pixel by pixel the resting fluorescence anisotropy map from the stimulated fluorescence anisotropy map over the entire maps or within an area of interest. 17. The method of claim 12, wherein the tissue dysfunction comprises presence and severity of a disease. 18. The method of claim 17, wherein the disease comprises cancer. 19. The method of claim 17, wherein the disease is selected from the group consisting of ocular posterior pathologies including diabetic retinopathy, age-related macular degeneration and primary open angle glaucoma, and other optic neuropathies. 20. The method of claim 12, wherein the stimulating comprises irradiating the tissue with steady-state light and the tissue is selected from the group consisting of skin tissue, cervix tissue, abdominal tissue, esophagus tissue, stomach tissue, gut tissue, lung tissue, and ocular tissue. 21. The method of claim 12, further comprising determining, based at least in part on the functional capacity of the tissue, an efficacy of a treatment intervention. 22. The method of claim 12, wherein a wavelength of the steady-state light is selected from a range between 400 and 700 nm.